LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that the Company will be hosting a Key Opinion Leader (KOL) webinar on the topic of treatment resistant depression (TRD) at 1:00p.m. ET on Tuesday, September 29, 2020. The webinar will discuss the role of neuroinflammation in TRD and will feature presentations by two highly-regarded thought leaders in the field: Charles Raison, M.D., professor in the department of psychiatry at the University of Wisconsin at Madison, and John E. Schneider, Ph.D., chief executive officer and principal of Avalon Health Economics.